尿石通丸联合盐酸坦洛新缓释胶囊治疗慢性前列腺炎合并前列腺结石疗效研究

Clinical study on treatment of chronic prostatitis complicated with Prostate Glioclones with urinary stone pill combined with Tylenol Hydrochloride Sustained Release Capsule

目的探究尿石通丸联合盐酸坦洛新缓释胶囊治疗慢性前列腺炎合并前列腺结石的疗效。方法选取兰溪市人民医院就医的76例慢性前列腺炎合并前列腺结石患者作为本次研究的对象。对76例患者进行分组,单一组38例患者应用盐酸坦洛新缓释胶囊治疗,联合组38例患者在单一组患者的基础上联合尿石通丸治疗,对比2组患者的慢性前列腺炎症状指数（NIH-CPSI）、临床疗效、前列腺液中白细胞水平及不良反应发生率。结果联合组患者的总有效率为94.74%,相比单一组（76.32%）明显更高,差异具有统计学意义（P〈0.05）;联合组患者治疗后NIH-CPSI及前列腺液中白细胞水平相比单一组明显更低,差异具有统计学意义（P〈0.05）;单一组不良反应发生率为7.89%,与联合组（5.26%）比较差异无统计学意义。结论尿石通丸联合盐酸坦洛新缓释胶囊治疗慢性前列腺炎合并前列腺结石效果显著,切实可行。

Objective To study the effect of urine stone pills combined with tamsulosin hydrochloride sustained-release capsules in the treatment of chronic prostatitis with prostatic calculi.Methods 76 patients with chronic prostatitis with prostate stones who had been hospitalized were treated as 76 patients in this study.A total of 38 patients in a single group were treated with tylosine hydrochloride sustained-release capsules.38 patients in the combined group were treated with Urethomide Pill on the basis of a single group of patients.The chronic prostatitis symptom index（NIH-CPSI） Clinical efficacy,white blood cell levels in prostatic fluid and the incidence of adverse reactions.Results The total effective rate was 94.74 % in the combined group,which was significantly lower than that in the single group（76.32 %）（P〈0.05）;the NIH-CPSI and prostatic fluid in the combined group were significantly lower than those in the single group（P〈0.05）,the incidence of adverse reactions in a single group was 7.89 %,and there was no significant difference between the combined group（5.26 %）.Conclusion The treatment of chronic prostatitis with prostatic calculi is significant and feasible.